Australia's Race Oncology jumps on improved drug formulation

Racura Oncology

28/09/2022 02:11

** Shares of Race Oncology Ltd  RAC.AX  rise as much as 6.3%
to A$2.04, stock to see best day since July 6 if gains hold 
    ** Co says it has developed new formulation of Zantrene that
enables the drug to be injected through arms or legs of patients
 urn:newsml:reuters.com:*:nASX88tYDC
    ** Zantrene is a drug being developed by co to treat certain
types of cancers such as skin and kidney 
    ** Shares of co hit their highest since Sept. 20 
    ** Stock down 46.7% YTD, as of last close
 (Reporting by John Biju in Bengaluru)
 ((John.Biju@thomsonreuters.com;))